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Aims Familial hypercholesterolaemia (FH) is a vastly under-diagnosed genetic disorder, associated with early develop-
ment of coronary heart disease and premature mortality which can be substantially reduced by effective treatment.
Patents have recently expired on high-intensity statins, reducing FH treatment costs. We build a model using UK
data to estimate the cost effectiveness of DNA testing of relatives of those with monogenic FH.
...................................................................................................................................................................................................
Methods
and results
A Markov model was used to estimate the cost effectiveness of cascade testing, using data from UK cascade ser-
vices. The estimated incremental cost effectiveness ratio (ICER) was £5806 and the net marginal lifetime cost per
relative tested was £2781. More than 80% of lifetime costs were diagnosis-related and incurred in the 1st year. In
UK services, 23% of 6396 index cases were mutation-positive. For each mutation-positive index case, 1.33 relatives
were tested, resulting overall in a rate of 0.31 tested relatives per tested index case. If the number of relatives
tested per tested index case rose to 3.2 (projected by National Institute for Health and Care Excellence in 2008)
the ICER would reduce to £2280 and lifetime costs to £1092.
...................................................................................................................................................................................................
Conclusion Cascade testing of relatives of those with suspected FH is highly cost effective. The current Europe-wide high levels
of undiagnosed FH, and associated morbidity and mortality, mean adoption of cascade services should yield sub-
stantial quality of life and survival gains.
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Introduction
Familial hypercholesterolaemia (FH) is an autosomal-dominant dis-
order associated with elevated low density lipoprotein cholesterol
(LDL-C) and early development of atherosclerosis and coronary heart
disease (CHD). Untreated, at least 50% of men with FH will develop
CHD by age 50, and 30% of women by age 60.1,2 The risk of CHD
death at age 20–39 is increased 80–84-fold FH.3 Treatment with statins
reduces the risk of CHD to approximately general population levels.4
Historically it has been estimated that 1/500 people has FH, around
130 000 in the UK, 1.5 million in Europe and 15 million worldwide, al-
though recent epidemiological data from Denmark5 and next
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generation sequencing data6 suggest the frequency may be approxi-
mately 1/250. Although some countries such as the Netherlands have
well established cascade testing programmes, most do not. The vast
majority of those with FH, worldwide, are undiagnosed.7
In 2008, the National Institute for Health and Care Excellence
(NICE) in England published guidelines for identification and manage-
ment of FH.8 These guidelines, like those elsewhere in Europe, rec-
ommended cascade testing of relatives of index cases, and estimated
the cost-effectiveness of such testing. Testing programmes were set
up in Scotland, Wales, and Northern Ireland. No national programme
exists in England; commissioning responsibility is divided between
211 local organizations. In much of the country there is no FH testing
programme at all.
Since the NICE guideline, much has changed. Patents have expired
on some high-intensity statins used to treat FH, leading to substantial
cost reductions, while next generation sequencing has reduced the
cost of DNA tests. There is now convincing evidence that in patients
with a clinical diagnosis of FH but no mutation in any of the three
known FH-causing genes (LDLR, APOB, and PCSK9),9,10 the most likely
cause of elevated LDL-C is polygenic.11 In polygenic FH the risk of
relatives having significantly raised LDL-C is much lower12 than
the 50% observed for monogenic hypercholesterolaemia.9 Finally,
the establishment of FH cascade services in parts of the UK provides
an opportunity to use real-life data rather than projections in eco-
nomic modelling. UK audit data, combined with new evidence on the
association between LDL-C reduction and CHD risk13 allow for
modelling based explicitly on observed LDL-C reductions in FH.
In this article, we use data from FH cascade services to inform an
economic model re-examining the cost effectiveness in the UK of
cascade testing for monogenic FH from known index cases, incorpo-
rating new study evidence, and changes in costs and clinical practice
that have occurred since the 2008 guideline.
Methods
Data were collected from FH cascade services in Scotland, Wales and the
Wessex region of England on people with clinically diagnosed FH who
have had DNA tests, rates of monogenic FH diagnosis in this group (i.e. a
detected FH-causing variant in LDLR, APOB, or PCSK9), and numbers of
relatives DNA tested. Additional data were collected from Wales on the
age-distribution and LDL-C levels at diagnosis of monogenic relatives,
and resource use. Data on sections of the pathway were collected from
Northern Ireland.
An economic model was developed to estimate the cost effectiveness
of a cascade testing pathway with three steps: DNA testing of people
who already have a clinical diagnosis of possible or definite FH (index
cases), DNA testing of relatives of monogenic index cases, and treatment
with high-intensity statins and, in some cases, ezetimibe for monogenic
relatives, relative to no DNA tests, no cascade testing and no treatment
of relatives (Figure 1).
It was assumed that, in both the intervention and non-intervention
arms of the model, index cases are treated appropriately for FH. The out-
come of the DNA test does not change the treatment of index cases. No
costs or benefits were counted for identification or treatment of index
cases, nor for treatment of relatives who do not carry the family
mutation.
A Markov model was used to estimate the cost, adverse event, and
Quality-adjusted-life-year (QALY) impacts of treatment for monogenic
relatives, compared with no treatment.14 The cycle length was one year.
Markov states are shown in Figure 2.
Pooled data from cascade services in Scotland, Wales and Wessex
were used in base case analysis to estimate monogenic diagnosis rates in
index cases and the number of relatives tested per monogenic index
case. Northern Ireland data were excluded from the pool, as they do not
cover the entire pathway, but were used in sensitivity analysis.
It was assumed in the base case that, once diagnosed, 86.25% of mono-
genic adult relatives take statins, and 46.43% also take ezetimibe, as re-
ported in a recent FH audit in the UK.15 In sensitivity analysis, we
modelled the impact of a 70% statin compliance rate, with a proportion-
ate reduction in ezetimibe.
It was assumed that 72% of those treated take atorvastatin, 20% sim-
vastatin and 8% rosuvastatin.16 The distribution of adult daily dosages for
each medication was taken from the 2010 audit.15 In sensitivity analysis,
we modelled the impact of a reduction in the price of rosuvastatin and
ezetimibe when UK patent protection ends in 2017.
The model was run for seven representative patient groups, aged (at
diagnosis) 20–24, 25–34, 35–44, 45–54, 55–64, 65–74, and 75þ. The age
distribution of patients at diagnosis was estimated from data supplied by
the Welsh FH service. It was assumed that relatives diagnosed through
cascade testing have no history of cardiovascular events.
Baseline (untreated) primary cardiovascular (CVD) risk by 5-year age-
band and gender for the general population was estimated using the
QRISK2-2016 calculator.17 The general population risk of individual car-
diovascular events (MI, angina, TIA, stroke, CVD death) was estimated by
applying the estimates of the distribution of these events from the NICE
Clinical Guideline on Cardiovascular Disease 18118 to the QRSIK esti-
mates. CHD death risk was estimated by examining the proportion of
CVD deaths attributed to CHD in ONS 2014 mortality data for England
and Wales19 in each 5-year age-band, and applying this proportion to esti-
mated CVD death risk. (CVD was identified by International
Classification of Diseases-10 (ICD-10) codes G45, I20–25, I50, I60–64,
and I73, and CHD by ICD-10 codes I20–25).
Figure 1 Structure of economic model.
*It is assumed that appropriate treatment is provided for index
cases and, where applicable, for mutation-negative relatives. Any
change to treatment for these groups as a result of DNA testing is
outside the scope of the model.
2 M. Kerr et al.
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.FH-specific primary risks of angina, MI and CHD death were estimated
by applying the relative risks reported for the Simon Broome FH register
population in 1980–923 to the general population baseline primary risks
for each age-band (adjusting for the inclusion of the FH group in the gen-
eral population figures). Simon Broome relative risks relate to CHD mor-
tality rather than to total CHD events. They were used here as a proxy
for CHD event relative risk. Simon Broome reported no increased risk of
death from stroke or TIA in FH.20 Unadjusted general population risks
were therefore used for stroke, TIA and non-CHD CVD death. For
age >_80, it was assumed that the risk of cardiovascular events in FH is as
for the general population. Estimated baseline risks are given in
Supplementary material online.
Secondary risk was estimated for seven age-bands, 20–24, 25–34, 35–
44, 45–54, 55–64, 65–74, and 75þ. Secondary risks for those aged 45–74
were taken from NICE 181.18 Risks for ages <45 and >74 were not pro-
vided in NICE 181. To estimate risk for ages 20–24, 25–34, and 35–44,
we examined the per capita rate of hospital admissions with cardiovascu-
lar events as primary diagnoses, in hospital episode statistics (HES), for
England in 2014–15, for each of these age-bands, relative to the per capita
rate for age 45–54. Cardiovascular events were identified by ICD-10
codes as above. Population by age-band was taken from Office for
National Statistics (ONS) 2014 mid-year population estimates for
England.21 The ratio of per capita events in each age-band relative to the
per-capita rate for age 45–54 was applied as a scaling factor to the age
45–54 transition probabilities in NICE 181 to estimate risks for ages 20–
24, 25–34, and 35–44. For ages 75þ, the ratio of per capita events in this
age group, relative to that for age 65–74 was applied as a scaling factor to
the age 65–74 transition probabilities. It was assumed that, in general, sec-
ondary risks in FH do not differ from secondary risks in the general popu-
lation. However, in cases where the general population secondary risk
was lower than the FH primary risk, the primary risk estimate was used.
Non-CVD mortality was estimated from ONS mortality data, by 5-year
age-band.
Given that there are no large-scale studies of treatment effects in FH,
treatment risk ratios were estimated using evidence from the cholesterol
treatment trialists’ collaborators (CTTC) study, which linked absolute re-
ductions in LDL-C to cardiovascular relative risk.13 While CTTC focused
on primary events, we assumed that the relative risk reduction is the
same for secondary events. Rate ratios for MI were applied also to angina,
and those for stroke were applied also to TIA. Model outputs were
sense-checked against existing small-scale FH studies.
It was assumed that mean baseline levels of LDL-C, for monogenic
relatives by age-band, are as observed by the Welsh FH cascade service.
In the base case it was assumed that the mean reduction in LDL-C for
treated patients is 37%, as observed in the 2010 UK FH audit.15 In sensi-
tivity analysis we modelled the impact of a 50% reduction in LDL-C, the
target recommended by NICE. In the base case it was assumed that the
37% reduction in LDL-C is achieved after cascade testing, for all
treatment-compliant monogenic relatives. It is known, however, that
some relatives are already taking cholesterol-lowering medication before
receiving their DNA test results (though it is not known whether they
started statins before the cascade-testing process began, or whether
treatment was changed after monogenic diagnosis). In sensitivity analysis
we modelled the impact of assuming no change in treatment after cas-
cade testing for those already on statins before monogenic diagnosis (and
thus no reduction in LDL-C associated with cascade testing). Some
monogenic relatives are normocholesterolemic at diagnosis. In sensitivity
analysis we modelled the impact of assuming no treatment and no health
impact for this group.
The net cost and QALY impacts of testing and treatment, per relative
participating in cascade testing, were estimated. The cost of DNA testing
for index cases was apportioned across tested relatives.
Figure 2 Markov model health states.
Cost effectiveness of cascade testing for familial hypercholesterolaemia 3
Table 1 Costs of testing, treatment and adverse events
See references 15, 16, 18, 22, 23 and 24.
4 M. Kerr et al.
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A UK NHS perspective was used for costs. We examined costs and
benefits over a lifetime perspective, and also their profile over time. All
costs were expressed in 2014-15 UK pounds. Costs and benefits were
discounted at 3.5% in the base case, and adjusted in sensitivity analysis.
Cost sources are given in Table 1.
It was assumed that clinical effectiveness of statins continues undimin-
ished throughout life. Health state utilities were taken from NICE 181.
We assumed that statin treatment does not of itself reduce utility,25 and
that the same is true of ezetimibe.
Results
Since the Welsh, Scottish and Wessex FH services were established,
6,396 clinically diagnosed FH index cases have had DNA tests. Of these,
22.98% had an FH-causing monogenic mutation. On average, 1.33 rela-
tives were tested per monogenic index case. In Northern Ireland, no
data were available on index cases tested. The number of relatives tested
per monogenic index case was 6.83 (Supplementary material online).
In Wales, mean baseline LDL-C in monogenic relatives was
6.67mmol/L, and levels ranged from 5.59 in those aged<_19, to 8.30 in
those aged>_55 (Table 2). Estimated relative risks associated with 37%
and 50% reductions in LDL-C, respectively, based on CTTC estimates of
the impact of absolute reductions in LDL-C on cardiovascular relative
risk, and Welsh data on baseline LCL-C, are shown in Supplementary ma-
terial online. In Wales, 41.66% of diagnosed monogenic relatives were tak-
ing cholesterol-lowering medication before receiving their DNA results.
Of those aged>_20, 8.89% were normocholesterolemic.
The economic model estimates that, for every 1,000 relatives
tested, over 20 years 46 MIs, 50 cases of angina, 8 strokes and 16
deaths are averted (Table 3).
The estimated incremental cost effectiveness ratio (ICER) of DNA
testing, cascade testing and treatment of relatives ranges from £4889
per relative tested in those aged 20-34, to £11 072 in those aged >_75
(Table 4). For a cohort with the age-distribution observed in the
Welsh cascade service the ICER is £5806 and the overall net marginal
lifetime cost per relative tested is £2781.
The net annual cost per tested relative is £2268 in year 1. Net
annual costs drop to £96 per tested relative in year 2, and are nega-
tive or <£2 from year 18 (Supplementary material online). Four fifths
of total lifetime costs are for the initial tests, and almost two thirds
are for DNA tests in index cases. The total cost per tested relative is
highly sensitive to the ratio of relatives tested to index cases tested. If
the number of relatives tested per tested index case rose from 0.31
(Scotland, Wales and Wessex mean) to 3.2 (projected by NICE in
2008) the ICER would reduce to £2280 and lifetime costs to £1092.
In sensitivity analysis, increasing the mean reduction in LDL-C to
50% reduces the ICER by 22%, and a reduction in treatment compli-
ance to 70% increases it by 19%. Estimated reductions in the prices of
rosuvastatin and ezetimibe, after patent expiry, reduce the net cost
and ICER by 32%. A shift in the ratio of relatives to probands to the
level observed in Northern Ireland reduces the net cost and ICER by
54%. Excluding treatment costs and effects for those taking statins be-
fore diagnosis reduces the net cost by 6% and increases the ICER by
71%. Reducing the discount rate to 1.5% reduces the ICER by 44%,
and increasing the discount rate to 5% increases the ICER by 44%.
Excluding treatment costs and effects for those with
....................................................................................................................................................................................................................
Table 2 Age distribution and mean LDL-C (mmol/L) at diagnosis, mutation-positive relatives, Wales
Age 0–19 20–24 25–34 35–44 45–54 551
% of all mutation-positive relatives 26.64% 8.30% 18.78% 19.21% 13.97% 13.10%
Mean LDL-C (95% CI)a 5.59 (5.33–5.86) 5.89 (5.13–6.64) 6.54 (6.04–7.03) 7.27 (6.62–7.92) 7.03 (6.26–7.79) 8.30 (7.35–9.25)
Normocholesterolemia, % of
age group
13.11% 21.05% 11.63% 6.82% 15.63% 0.00%
Mean LDL-C (95% CI) excluding
normocholesterolemic
5.82 (5.56–6.08) 6.36 (5.54–7.18) 6.90 (6.45–7.35) 7.51 (6.88–8.15) 7.57 (6.71–8.42) 8.30 (7.35–9.25)
LDL-C, low density lipoprotein cholesterol.
aBaseline LDL-C estimated from correction tables in 26% of cases.
.................................................................................................
Table 3 Estimated adverse events averted (cumula-
tive) per 1000 relatives tested
Years
after
testing
Myocardial
infarction
Stroke Unstable
angina
Stable
angina
Deaths
5 10 1 3 12 2
10 22 3 8 22 7
20 46 8 14 36 16
30 67 13 17 42 23
.................................................................................................
Table 4 Lifetime net cost, ICER and QALY impacts of
cascade testing per tested relative
Age Lifetime
cost
Lifetime
QALY gain
ICER
20–34 £2722 0.56 £4889
35–44 £2943 0.46 £6369
45–54 £2789 0.48 £5770
55–64 £2732 0.36 £7587
65–74 £2495 0.31 £8056
75þ £2285 0.21 £11072
Cohort £2781 0.48 £5806
ICER, incremental cost effectiveness ratio; QALY, quality-adjusted-life-year.
Cost effectiveness of cascade testing for familial hypercholesterolaemia 5
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..normocholesterolemia at DNA diagnosis increases the ICER by 5%
(Table 5 and Supplementary material online).
The reduction in CHD mortality in treated relatives is estimated at
44%, based on a mean LDL-C reduction of 37%, and 55% with a mean
50% LDL-C reduction. The Simon Broome study reported a 48% re-
duction in CHD mortality for those without prior CHD.26 Our model
estimates a 60.7% reduction in myocardial infarction (MI) over 8 years
for treated relatives achieving a 37% reduction in LDL-C, and 68.6%
for a mean 50% LDL-C reduction. Versmissen4 did not report specific-
ally on MI risk, but found an overall CHD risk reduction of 76% (hazard
ratio 0.24 (95% CI 0.18-0.30), over mean follow-up time of 8.5 years.
Discussion
The reduction in unit costs for genetic testing and the expiry of pa-
tents for high-intensity statins make re-examination of the cost effect-
iveness of cascade testing for FH important for all countries. We
were able to use data from UK FH cascade services to replace key as-
sumptions of the NICE 2008 model, and to use the findings of recent
clinical studies examining the link between cardiovascular risk and
treatment-induced reductions in LDL-C, an approach which is likely
to be more appropriate to FH than the use of population-level
relative risks. However, in common with all economic studies of FH,
we are restricted by the lack of large-scale studies on treatment ef-
fects in FH. We have assumed that FH patients respond to statins in
the same way as non-FH patients, and also that treatment effects are
undiminished over time. We have also assumed that compliance
rates are the same across all age groups, and are sustained over a life-
time. We have sense-checked our model outputs against data from
existing small-scale FH studies, and believe that our findings are com-
patible with those results. Exact comparison is not possible, as exist-
ing studies do not match the model in treatment regimes, achieved
LDL-C reductions or patient characteristics. Our model excludes
children because of lack of data to assess effectiveness.
Our economic model suggests that cascade testing in families with
FH is highly cost effective. Our base case estimates the cost per
QALY (ICER) of DNA cascade testing at £5806 per tested relative,
considerably below the cost effectiveness threshold of £20 000-
£30 000 commonly used in the English NHS. Over a 30-year perspec-
tive, we estimate that 139 adverse CVD events and 23 deaths are
averted per 1,000 relatives tested, at a cost of £2.8 million (Figure 3).
Health gains and cost effectiveness are negatively related to age at
diagnosis. The cost per QALY is 57% higher in those aged >_ 55 than
in those aged 20-54.
....................................................................................................................................................................................................................
Table 5 Sensitivity analyses: lifetime net cost, QALYand ICER impacts
Sensitivity analysis Lifetime cost Lifetime QALY gain ICER
1: 50% LDL-C reduction £2560 0.57 £4503
2: Northern Ireland relative: monogenic proband ratio £1277 As base case £2667
3: 70% compliance £2672 0.39 £6874
4: Rosuvastatin and ezetimibe cost reduction £1882 As base case £3929
5: Discount rate 1.5% £2773 0.85 £3278
6: Discount rate 5% £2771 0.33 £8387
7: No treatment change if already on statins £2615 0.26 £9954
8: No treatment change if normocholesterolemic £2686 0.44 £6069
ICER, incremental cost effectiveness ratio; QALY, quality-adjusted-life-year.
Figure 3 Adverse events averted, net cost and incremental cost effectiveness ratio after 30 years per 1000 relatives tested.
6 M. Kerr et al.
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These estimates are highly sensitive to the number of relatives
tested per index case tested. Increasing the yield of monogenic diag-
noses in index cases would significantly increase cost effectiveness, all
other things equal. Currently 65% of lifetime costs are for index case
testing and the monogenic detection rate is 22.98%. Increasing the
number of relatives tested per monogenic index case would also in-
crease cost effectiveness. Data from Northern Ireland indicate a con-
siderably higher yield of tested relatives than elsewhere in the UK,
with corresponding reductions in net costs, as shown in sensitivity
analysis. In regions of Europe where there has been less family disper-
sion than in the UK, or where families are larger, cost effectiveness
may be higher other things equal.
All the UK cascade services are relatively new, and it is likely that
the yield of relatives will increase over time. It is also likely that the in-
completeness of UK cascade services impacts testing rates for exist-
ing services; some relatives identified in the Welsh, Scottish and
Northern Irish services live in England, where there is very little
provision.
It is also important to note that many families with FH are com-
pletely undetected. There is a need for further study on the cost ef-
fectiveness of strategies for index case finding, and of approaches
such as reverse cascade testing from children identified at immuniza-
tion as having FH.27
The expiry of patents on atorvastatin and simvastatin has substan-
tially reduced the cost of statin treatment since the NICE guidance of
2008. UK patents for ezetimibe and rosuvastatin will expire in 2017.
We estimate that if, after patent expiry, the price of rosuvastatin
were to fall to the same level as that of atorvastatin (a reduction of
around 94%) and the price of ezetimibe were to fall by 90%, the life-
time cost of cascade testing would fall by a third.
Not all recent studies28,29 have found cascade testing for FH to be
as cost effective as we do here for the UK. For any programme, cost
effectiveness depends on the choice of comparator and the cost struc-
ture of interventions, which may vary substantially from place to place.
Recent CVD risk management guidelines suggest that some statin-
intolerant patients or those with high LDL-C on maximum tolerated
statin dose should be considered for treatment with novel agents
such as monoclonal antibodies to PCSK9.30 We were unable to in-
clude these in our model, owing to the lack of robust RCT end point
data and pricing data.
Any changes to the treatment of index cases or non-monogenic
relatives are outside the scope of the model. It is likely, however, that
in practice cascade testing would lead to changes in some cases and
this could have an impact on overall cost effectiveness. Further work
is needed on the impact of cascade testing on these groups.
It is hoped that the current study will lay the foundation for future
work, and will support commissioning decisions on FH services in
Europe and elsewhere.
Supplementary material
Supplementary material is available at European Heart Journal online.
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